Navigation Links
Mylan Receives Approval for Generic Version of Arimidex® Tablets
Date:6/29/2010

PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.

Anastrozole Tablets had U.S. sales of approximately $917 million for the 12 months ending March 31, 2010, according to IMS Health. The product is available for immediate shipment.

Currently, Mylan has 136 ANDAs pending FDA approval representing $94 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $20.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Zocor® Tablets
2. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
3. Mylan Receives Approval for Generic Version of Neurontin® Tablets
4. Mylan Receives Approval for Generic Version of Valtrex®
5. Mylan Launches Temazepam Capsules USP, 7.5 mg
6. Mylan Announces Completion of Senior Notes Offering
7. Mylan Announces Upsizing and Pricing of Senior Notes
8. Mylan Announces Proposed Senior Notes Private Placement
9. Mylan Receives Approval for Generic Version of Zyban(R)
10. Mylan Receives Approval for Generic Version of Flomax(R)
11. Mylan Schedules First Quarter 2010 Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
(Date:4/24/2017)... ... 2017 , ... Michael Vick announced his retirement earlier this year from the ... number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four ... most career rushing yards by a quarterback (6,109) and the most rushing yards by ...
(Date:4/24/2017)... ... 24, 2017 , ... As part of the nationwide Days of Remembrance effort ... the Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) ... Champions trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):